DOI QR코드

DOI QR Code

Incidentally Detected Adenocarcinoma Prostate in Transurethral Resection of Prostate Specimens: a Hospital Based Study from India

  • Varghese, Jophy (Department of Pathology, Lourdes Hospital) ;
  • Kuruvilla, Priya Mariam (Department of Pathology, Lourdes Hospital) ;
  • Mehta, Nisarg (Department of Urology, Lourdes Hospital) ;
  • Rathore, Ranjeet Singh (Department of Urology, Lourdes Hospital) ;
  • Babu, Manas (Department of Urology, Lourdes Hospital) ;
  • Bansal, Devesh (Department of Urology, Lourdes Hospital) ;
  • Pillai, Biju (Department of Urology, Lourdes Hospital) ;
  • Sam, Mohan P (Department of Urology, Lourdes Hospital) ;
  • Krishnamorthy, H (Department of Urology, Lourdes Hospital)
  • Published : 2016.06.01

Abstract

Background: Awareness about prostate cancer has increased in the community, and prostate cancer screening examinations, including prostate specific antigen (PSA) assays, are now widely available. Prior to the PSA era, up to 27% of prostate cancers were detected incidentally at the time of transurethral resection of prostate (TURP). After PSA testing became widely available, the incidence of incidentally detected carcinoma prostate in TURP specimens without prior diagnosis reduced to 5-13%. However, the incidence of incidentally detected carcinoma prostate has been reported to vary across the globe since various factors can influence the identification of this malignancy in TURP specimens. In this paper, we focus on rates of incidentally detected prostate cancer in TURP specimens in our hospital and correlate it with various parameters. Materials and Methods: This retrospective study of histopathological findings of biopsy specimens was conducted for patients undergoing TURP during a period of 5 years from April 2010. The inclusion criteria were patients diagnosed with benign prostatic hyperplasia (BPH) (digital rectal examination (DRE) not showing any abnormally hard areas and normal age adjusted PSA values). Patients with elevated PSA, abnormal DRE, documented urinary tract infection and proved adenocarcinoma prostate (CaP) were excluded from the study. The total weight of prostatectomy specimen, occurrence of carcinoma prostate in the chips, percentage of total tissue resected showing malignancy and Gleason's scores were recorded. Results: A total of 597 patients belonging to the inclusion criteria were studied. The incidence of occult CaP in the study group was 5.2 % (31/597). Out of these, 8 belonged to T1a and 23 belonged to T1b stages. The age group 70 - 79 years had the maximum incidence of occult CaP. It was observed that the clinical grading of prostate did not have a bearing on the incidence of occult CaP whereas the weight of resected specimen correlated with the incidence of CaP. The incidence of occult CaP was greater with low volume prostates (<20 g). (P=0.15). Conclusions: The rate of incidentally detected adenocarcinoma prostate in patients undergoing TURP for clinically diagnosed BPH was found to be only 5.2 % in our study which is low when compared with similar studies done elsewhere. The age of the patient and weight of the resected specimen correlated with incidence of occult prostate cancer. The clinical grading of prostate by DRE however, demonstrated no correlation.

Keywords

Incidental prostate cancer;transurethral resection of prostate (TURP);prostate specific antigen (PSA)

References

  1. Baade PD, Yu XQ, Smith DP, et al (2015). Geographic disparities in prostate cancer outcomes - review of international patterns. Asian Pac J Cancer Prev, 16, 1259-75. https://doi.org/10.7314/APJCP.2015.16.3.1259
  2. Bashir NM (2015). Epidemiology of prostate cancer. Asian Pac J Cancer Prev, 16, 5137-41. https://doi.org/10.7314/APJCP.2015.16.13.5137
  3. Catalona WJ, Richie JP, Ahmann FR, et al (1994). Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. J Urol 151, 1283-90. https://doi.org/10.1016/S0022-5347(17)35233-3
  4. Edge SB, Byrd DR, Compton CC, et al (2010). (Eds.) American joint committee on cancer (AJCC). Cancer staging manual. 7th edition. Springer, New York, NY.
  5. Epstein JI, Allsbrook WC Jr, Amin MB, et al (2005). ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol, 29, 1228-42. https://doi.org/10.1097/01.pas.0000173646.99337.b1
  6. Esfahani M, Ataei N, Panjehpour M (2015). Biomarkers for evaluation of prostate cancer prognosis. Asian Pac J Cancer Prev, 16, 2601-11. https://doi.org/10.7314/APJCP.2015.16.7.2601
  7. Fowler JE Jr, Pandey P, Bigler SA, et al (1997). Trends in diagnosis of stage T1a-b prostate cancer. J Urol, 158, 1849-52. https://doi.org/10.1016/S0022-5347(01)64144-2
  8. Jones JS, Follis HW, Johnson JR (2009). Probability of finding T1a and T1b (incidental) prostate cancer during TURP has decreased in the PSA era. Prostate Cancer Prostatic Dis; 12, 57-60. https://doi.org/10.1038/pcan.2008.14
  9. Kash DP, Lal M, Hashmi AH, et al (2014). Utility of digital rectal examination, serum prostate specific antigen, and transrectal ultrasound in the detection of prostate cancer: a developing country perspective. Asian Pac J Cancer Prev, 15, 3087-91. https://doi.org/10.7314/APJCP.2014.15.7.3087
  10. Melchior S, Hadaschik B, Thuroff S, et al (2008). Outcome of radical prostatectomy for incidental carcinoma of the prostate. BJU International, 103, 1478-81.
  11. Oesterling JE, Jacobsen SJ, Chute CG et al (1993). Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA, 270, 860-4. https://doi.org/10.1001/jama.1993.03510070082041
  12. Saleh AM, Fooladi MM, Nustas WP, et al (2015). Enhancing knowledge, beliefs, and intention to screen for prostate cancer via different health educational interventions: a literature review. Asian Pac J Cancer Prev, 16, 5137-41. https://doi.org/10.7314/APJCP.2015.16.13.5137
  13. Tombal B, De Visccher L, Cosyns JP, et al (1999). Assessing the risk of unsuspected prostate cancer in patients with benign prostatic hypertrophy: a 13-year retrospective study of the incidence and natural history of T1a-T1b prostate cancers, BJU International, 84, 1015-20.
  14. Yoo C, Oh CY, Kim SJ, et al (2012). Preoperative clinical factors for diagnosis of incidental prostate cancer in the era of tissueablative surgery for benign prostatic hyperplasia: A Korean multi-center review. Korean J Urol, 53, 391-5. https://doi.org/10.4111/kju.2012.53.6.391
  15. Zigeuner RE, Lipsky K, Riedler I et al (2003). Did the rate of incidental prostate cancer change in the era of PSA testing? A retrospective study of 1127 patients. Urol, 624, 451-5.